{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T02:31:22Z","timestamp":1749263482041,"version":"3.37.3"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To examine the potential of cyclin D1\/podoplanin dual immunohistochemical stain to differentiate malignant mesothelioma from reactive mesothelial proliferations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Cyclin D1\/podoplanin dual immunohistochemistry was performed on 34 surgical cases of reactive mesothelial proliferations, malignant mesothelioma, and nonmesothelioma malignancies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All 15 reactive mesothelial proliferations demonstrated less than 50% cyclin D1 staining with variable to diffuse podoplanin staining. In 6 (60%) of 10 cases of epithelioid malignant mesothelioma, the dual stain supported the diagnosis. Less than 50% cyclin D1 staining was noted in the remaining four cases, including small biopsy specimens or cases with focal papillary architecture. The five cases of sarcomatoid\/desmoplastic\/biphasic mesothelioma showed more than 50% cyclin D1 staining with focal to absent podoplanin staining. Well-differentiated papillary mesothelioma appears to demonstrate less than 25% cyclin D1 staining.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The cyclin D1\/podoplanin dual stain is reliable and may be used to aid in differentiation of benign mesothelial proliferations from malignant tumors. In addition, histologic features and other ancillary testing may support the classification of cases with an inconclusive cyclin D1\/podoplanin staining.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqac022","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T04:11:43Z","timestamp":1643775103000},"page":"187-198","source":"Crossref","is-referenced-by-count":2,"title":["Usefulness of Cyclin D1\/Podoplanin Dual Immunohistochemical Stain to Differentiate Malignant Mesothelioma From Reactive Mesothelial Proliferations"],"prefix":"10.1093","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3905-1481","authenticated-orcid":false,"given":"Raghavendra","family":"Pillappa","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Virginia Commonwealth University , Richmond, VA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-4333","authenticated-orcid":false,"given":"Austin","family":"Wiles","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Virginia Commonwealth University , Richmond, VA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadia","family":"Sayeed","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Virginia Commonwealth University , Richmond, VA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4542-7238","authenticated-orcid":false,"given":"Valentina","family":"Robila","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Virginia Commonwealth University , Richmond, VA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"2022080409000906400_CIT0001","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.path.2019.10.001","article-title":"Diagnosis of mesothelioma","volume":"13","author":"Fels Elliott","year":"2020","journal-title":"Surg Pathol Clin."},{"key":"2022080409000906400_CIT0002","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer."},{"key":"2022080409000906400_CIT0003","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1097\/PAS.0000000000001565","article-title":"The separation of benign and malignant mesothelial proliferations: new markers and how to use them","volume":"44","author":"Churg","year":"2020","journal-title":"Am J Surg Pathol."},{"key":"2022080409000906400_CIT0004","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41379-019-0411-9","article-title":"Cyclin D1 immunohistochemical staining to separate benign from malignant mesothelial proliferations","volume":"33","author":"Pors","year":"2020","journal-title":"Mod Pathol."},{"key":"2022080409000906400_CIT0005","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s12105-019-01016-2","article-title":"Utility and practicality of multi-level sectioning and upfront unstained slide cutting in head and neck biopsies: a critical analysis","volume":"13","author":"Saab-Chalhoub","year":"2019","journal-title":"Head Neck Pathol."},{"key":"2022080409000906400_CIT0006","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med."},{"key":"2022080409000906400_CIT0007","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1309\/TYE7K2CQMQ707FRT","article-title":"Antibody selection in immunohistochemical detection of cyclin D1 in mantle cell lymphoma","volume":"124","author":"Torlakovic","year":"2005","journal-title":"Am J Clin Pathol."},{"key":"2022080409000906400_CIT0008","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s00109-016-1475-3","article-title":"Cyclin D1, cancer progression, and opportunities in cancer treatment","volume":"94","author":"Qie","year":"2016","journal-title":"J Mol Med (Berl)."},{"key":"2022080409000906400_CIT0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2006.09.024","article-title":"Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation","volume":"55","author":"Gautschi","year":"2007","journal-title":"Lung Cancer"},{"key":"2022080409000906400_CIT0010","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12967-019-1869-4","article-title":"Analysis of the role of the Hippo pathway in cancer","volume":"17","author":"Han","year":"2019","journal-title":"J Transl Med."},{"key":"2022080409000906400_CIT0011","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.5858\/arpa.2018-0273-OA","article-title":"Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas","volume":"142","author":"Berg","year":"2018","journal-title":"Arch Pathol Lab Med."},{"key":"2022080409000906400_CIT0012","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/PAS.0000000000000976","article-title":"Loss of BAP1 expression in atypical mesothelial proliferations helps to predict malignant mesothelioma","volume":"42","author":"Pillappa","year":"2018","journal-title":"Am J Surg Pathol."},{"key":"2022080409000906400_CIT0013","doi-asserted-by":"crossref","first-page":"185","DOI":"10.5858\/arpa.2019-0370-OA","article-title":"Use of programmed death ligand-1 (PD-L1) staining to separate sarcomatoid malignant mesotheliomas from benign mesothelial reactions","volume":"144","author":"Derakhshan","year":"2020","journal-title":"Arch Pathol Lab Med."},{"key":"2022080409000906400_CIT0014","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/his.13468","article-title":"Malignant mesothelioma in situ","volume":"72","author":"Churg","year":"2018","journal-title":"Histopathology."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/158\/2\/187\/45228617\/aqac022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/158\/2\/187\/45228617\/aqac022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T09:01:21Z","timestamp":1659603681000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/158\/2\/187\/6548252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":14,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,3,14]]},"published-print":{"date-parts":[[2022,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqac022","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"type":"print","value":"0002-9173"},{"type":"electronic","value":"1943-7722"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,3,14]]}}}